You are here: Industry Insights > CKD

News List

FDA approves AstraZeneca’s Farxiga for chronic kidney disease treatment pharmaceutical-technology
May 06, 2021
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Farxiga (dapagliflozin) for treating chronic kidney disease (CKD) in patients who are at the risk of progression with and without type-2 diabetes.
Bayer announces FDA accepts NDA and grants priority review for Finerenone for patients with CKD and T2D pharmaceutical-business-review
January 18, 2021
Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted Priority Review for finerenone, an investigational drug for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).
Farxiga Granted Priority Review in US for Chronic Kidney Disease americanpharmaceuticalreview
January 14, 2021
AstraZeneca’s Farxiga (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).
US priority review for Forxiga in chronic kidney disease pharmatimes
January 07, 2021
The US Food and Drug Administration (FDA) has granted AstraZeneca’s Forxiga (dapagliflozin) a priority review for the treatment of new or worsening chronic kidney disease (CKD).
AZ presents new real-world chronic kidney disease data at ASN 2020 pharmatimes
October 28, 2020
AstraZeneca presented new findings from the DISCOVER Chronic Kidney Disease (CKD) study at the American Society of Nephrologists (ASN) Kidney Week 2020 Congress last week.
Ardelyx Announces NDA Acceptance of Tenapanor americanpharmaceuticalreview
September 22, 2020
Ardelyx announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
Akebia Announces Top-Line Results from Vadadustat Study americanpharmaceuticalreview
September 07, 2020
Akebia Therapeutics announces top-line results from PRO2TECT, the second of its two global Phase 3 cardiovascular outcomes programs.
Diabetes drug, Dapagliflozin shows benefits in patients with CKD expresspharma
September 01, 2020
The drug, on top of standard of care, reduced the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39 per cent.
AZ partners with RenalytixAI in chronic disease pact pharmatimes
August 24, 2020
AstraZeneca has linked with RenalytixAI to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases.
Evotec and Novo Nordisk Form Strategic Alliance contractpharma
August 19, 2020
Evotec SE and Novo Nordisk have announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease.

Previous page 1 2 3 4 5 6 Next page